Transition Therapeutics Inc (TTH.TO) 7.05 $TTH.TO
Transition Therapeutics hires Carl Damiani as COO
M2 - Fri Jul 11, 6:51AM CDT
Biopharmaceutical company Transition Therapeutics (NASDAQ:TTHI)(TSX:TTH) announced on Friday the appointment of Carl Damiani as its chief operating officer.
Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer
PR Newswire - Fri Jul 11, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) Chairman and Chief Executive Officer, Dr. Tony Cruz is pleased to announce that Carl Damiani has been appointed to the role of Chief Operating Officer of Transition.
Transition Therapeutics Announces Closing of Private Placement Equity Financing
CNW Group - Mon Jun 23, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI) (TSX: TTH) announced that it has closed its previously announced private placement through which 3,195,487 units of the Company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders. Gross proceeds of the private placement totalled US$17 million.
Transition Therapeutics expects up to USD30.8m in equity financing of units
M2 - Mon Jun 09, 6:20AM CDT
Biopharmaceutical company Transition Therapeutics (NASDAQ:TTHI)(TSX:TTH) said on Friday that it expects to raise up to USD30.8m through the sale of 3,195,487 units at a price of USD5.32 per unit.
IIROC Trade Resumption - TTH
CNW Group - Fri Jun 06, 8:13AM CDT
Trading resumes in:
IIROC Trading Halt - TTH (all issues)
CNW Group - Fri Jun 06, 8:05AM CDT
The following issues have been halted by IIROC:
Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$30.8 Million in Equity Financing
PR Newswire - Fri Jun 06, 8:01AM CDT
Company to Receive Upfront US$17 Million Upon Closing
Transition Therapeutics to Host Investor Day and Webcast on May 28th in New York City
PR Newswire - Tue May 27, 7:01AM CDT
Live Webcast Beginning at 8am Eastern Time on May 28th
Transition Therapeutics to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 22, 3:45PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Jefferies 2014 Global Healthcare Conference on Monday, June 2nd, at 8:30 a.m. Eastern Time in New York City.
Transition Therapeutics to Present at the 34th Annual Cowen & Co. Healthcare Conference
CNW Group - Mon Mar 03, 12:15PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI) (TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 34(th) Annual Cowen & Co. Healthcare Conference on Tuesday, March 4th, 2014 at 10:00 a.m. Eastern Time at the Boston Marriott Copley Place Hotel in Boston, MA.
Perrigo Company plc and Transition Therapeutics Modify Development and Commercialization Rights of ELND005 Program
CNW Group - Fri Feb 28, 6:25AM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) announced the acquisition of an Irish domiciled company ("Irish Subsidiary", the holder of all the development and commercialization rights of neuropsychiatric drug candidate, ELND005. The Company also announced a US$15 million investment by Perrigo to acquire approximately 7% of Transition's common shares. ELND005 is an oral drug candidate that is being evaluated in three studies: a Phase 2 study for Agitation and Aggression in Alzheimer's Disease, a Phase 2 study for Bipolar Disorder and a Phase 2A study in Down Syndrome.
Transition Therapeutics Announces Second Quarter Fiscal 2014 Financial Results
CNW Group - Wed Feb 12, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (TSX: TTH) (NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and six month periods ended December 31, 2013.
Transition Therapeutics hires Carl Damiani as COO
M2 - Fri Jul 11, 6:51AM CDT
Biopharmaceutical company Transition Therapeutics (NASDAQ:TTHI)(TSX:TTH) announced on Friday the appointment of Carl Damiani as its chief operating officer.
Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer
PR Newswire - Fri Jul 11, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) Chairman and Chief Executive Officer, Dr. Tony Cruz is pleased to announce that Carl Damiani has been appointed to the role of Chief Operating Officer of Transition. Transition Therapeutics Announces Closing of Private Placement Equity Financing
CNW Group - Mon Jun 23, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI) (TSX: TTH) announced that it has closed its previously announced private placement through which 3,195,487 units of the Company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders. Gross proceeds of the private placement totalled US$17 million. Transition Therapeutics expects up to USD30.8m in equity financing of units
M2 - Mon Jun 09, 6:20AM CDT
Biopharmaceutical company Transition Therapeutics (NASDAQ:TTHI)(TSX:TTH) said on Friday that it expects to raise up to USD30.8m through the sale of 3,195,487 units at a price of USD5.32 per unit.
IIROC Trade Resumption - TTH
CNW Group - Fri Jun 06, 8:13AM CDT
Trading resumes in:
IIROC Trading Halt - TTH (all issues)
CNW Group - Fri Jun 06, 8:05AM CDT
The following issues have been halted by IIROC:
Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$30.8 Million in Equity Financing
PR Newswire - Fri Jun 06, 8:01AM CDT
Company to Receive Upfront US$17 Million Upon Closing
Transition Therapeutics to Host Investor Day and Webcast on May 28th in New York City
PR Newswire - Tue May 27, 7:01AM CDT
Live Webcast Beginning at 8am Eastern Time on May 28th
Transition Therapeutics to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 22, 3:45PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Jefferies 2014 Global Healthcare Conference on Monday, June 2nd, at 8:30 a.m. Eastern Time in New York City. Transition Therapeutics to Present at the 34th Annual Cowen & Co. Healthcare Conference
CNW Group - Mon Mar 03, 12:15PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI) (TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 34(th) Annual Cowen & Co. Healthcare Conference on Tuesday, March 4th, 2014 at 10:00 a.m. Eastern Time at the Boston Marriott Copley Place Hotel in Boston, MA. Perrigo Company plc and Transition Therapeutics Modify Development and Commercialization Rights of ELND005 Program
CNW Group - Fri Feb 28, 6:25AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) announced the acquisition of an Irish domiciled company ("Irish Subsidiary", the holder of all the development and commercialization rights of neuropsychiatric drug candidate, ELND005. The Company also announced a US$15 million investment by Perrigo to acquire approximately 7% of Transition's common shares. ELND005 is an oral drug candidate that is being evaluated in three studies: a Phase 2 study for Agitation and Aggression in Alzheimer's Disease, a Phase 2 study for Bipolar Disorder and a Phase 2A study in Down Syndrome. Transition Therapeutics Announces Second Quarter Fiscal 2014 Financial Results
CNW Group - Wed Feb 12, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(TSX: TTH) (NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and six month periods ended December 31, 2013. 
